NICE has published final guidance recommending empagliflozin (Jardiance®, Boehringer Ingelheim) for the treatment of type 2 diabetes.
Empagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor and has been approved for the following indications:
- As dual therapy, in combination with metformin, if a sulphonylurea is contraindicated or not tolerated, or if there is significant risk of hypoglycaemia or its consequences.
- As triple therapy, in combination with metformin and a sulphonylurea or metformin and a thiazolidinedione.
- In combination with insulin, with or without other antidiabetes drugs.
The NHS now has a legal obligation to begin funding this treatment for eligible patients within the next 3 months.
The full guidance is available on the NICE website here.